MVR-C5252
Phase 1Biologic
MVR-C5252 is one of 50 biologic programs targeting Efficacy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
139 competitors in Efficacy
#DrugCompanyPhaseTrials
1Vabysmo
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Veracept
SSebela Women's Health Inc.
Phase 3
Cetaphil
GGalderma R&D
Phase 3
Aralen
SanofiPreclinical
Primaquine
SanofiPreclinical
Proamatine
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy1 trial
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
Recruiting·—·Phase 1·NCT06126744·51 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MVR-C5252. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- DDuke University